Cerebrolysin
Cerebrolysin is a peptide, indexed here under Neuroactive peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Neuroactive peptides |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Cerebrolysin is not a single compound. A 2012 CNS and Neurological Disorders Drug Targets paper describes it as a mixture of neurotrophic factors, and a 2012 Drugs of Today review covers the pharmacology of neurotrophic treatment with it. Because it is a preparation rather than a defined molecular entity, PubChem returned no compound record for the name and the identity fields on this record are therefore unsourced rather than estimated.
Its retrieved literature differs from the rest of this dataset in being largely clinical and concentrated on stroke recovery. A 2016 Stroke paper reports the Cerebrolysin and Recovery After Stroke randomised placebo-controlled trial, a 2012 Stroke paper reports a double-blind trial in acute ischaemic stroke in Asia, and a 2018 Neurological Sciences paper is a meta-analysis of early post-stroke recovery. Preclinical records include a 2010 Journal of Neuroscience Research paper on neurogenesis in the ischaemic brain and a 2013 Stroke paper on sonic hedgehog signalling. Those trials were conducted in jurisdictions where the preparation is registered; the Drugs@FDA register returned no application records for this name.
[2, 3, 4, 5, 6, 7, 8]Reported mechanism
Characterised in the retrieved records as a mixture of neurotrophic factors rather than a single molecular entity, so no single receptor target applies.
[2, 3]Stated in the title of the cited 2012 CNS and Neurological Disorders Drug Targets paper.
Targets named in the cited records: neurotrophic factor activity.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Cerebrolysin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- porcine brain peptide preparation
Where this page sits
Research records
Cited research records for Cerebrolysin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
Class page: Neuroactive peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Cerebrolysin?
Cerebrolysin is not a single compound. A 2012 CNS and Neurological Disorders Drug Targets paper describes it as a mixture of neurotrophic factors, and a 2012 Drugs of Today review covers the pharmacology of neurotrophic treatment with it.
Which class is Cerebrolysin indexed under?
Cerebrolysin is indexed under Neuroactive peptides. The compounds grouped here are peptides whose retrieved literature examines effects in the nervous system.
What does the FDA application register show for Cerebrolysin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cerebrolysin
- Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS & neurological disorders drug targets (2012). pmid:22229324
- The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of today (Barcelona, Spain : 1998) (2012). pmid:22514792
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke (2016). pmid:26564102
- Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke (2012). pmid:22282884
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2018). pmid:29248999
- Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of neuroscience research (2010). pmid:20857512
- Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke (2013). pmid:23696546
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.